Long-Acting Technologies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria

The Unitaid-funded LONGEVITY project aims to develop long-acting formulations for malaria and latent tuberculosis (TB) prevention and a single-injection cure for hepatitis C virus (HCV) for low- and middle-income countries, as these diseases disproportionately affect children, poor and marginalized communities, people who use drugs, and people living with HIV. This trials tracker provides information on the development of long-acting HCV, malaria, and opioid use and overdose prevention therapy formulations and serves as a single reliable source for ongoing trials given the potential to use the same nanotechnology platform to produce a mass scale of different long-acting formulations. Read more in this report.